CS3003 / CStone Pharma - LARVOL DELTA

[VIRTUAL] CS3003, an HDAC6-selective inhibitor, improves anti-PD-1 immune checkpoint blockade therapy efficacy (AACR-II 2020) - "These data provide a comprehensive pre-clinical characterization of CS3003 that supports its unique HDAC inhibition profile and its capability of improving anti-PD-1 immune checkpoint blockade therapy efficacy."

Checkpoint inhibition • Clinical • IO Biomarker • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor

CStone Pharmaceuticals Released Preclinical Data on its Four Pipeline Products (CStone Pharma Press Release) - "CS3003: The pre-clinical data presented at the 2020 AACR Virtual Annual Meeting II demonstrated the improved efficacy of CS3003 in combination with proteasome inhibitors and immune checkpoint inhibitors over mono-therapies, and revealed its unique modulation of gene expression as compared to other HDAC inhibitors."

Preclinical • Oncology

CStone Pharmaceuticals to present preclinical data on its three pipeline products at the 2020 AACR Virtual Annual Meeting (CStone Pharma Press Release) - "The pre-clinical data to be presented at the 2020 AACR Virtual Annual Meeting II demonstrate the improved efficacy of CS3003 in combination with the proteasome inhibitor or the anti-PD-1 therapy over mono-therapies, and reveal its unique modulation of gene expression as compared to other HDAC inhibitors."

Preclinical • Oncology

CStone received IND approval in China for HDAC6 inhibitor CS3003 (PRNewswire) - "CStone Pharmaceuticals (Suzhou) Co., Ltd. ("CStone", stock code: 2616.HK) announced that the National Medical Products Administration (NMPA) recently approved company's histone deacetylase 6 (HDAC6) selective inhibitor CS3003 for Phase I clinical trial in China. This is a multi-center, Phase I dose escalation study synchronously conducted in China and Australia in patients with advanced solid tumors and relapsed or refractory multiple myeloma."

New P1 trial • Non-US regulatory